Barchart on MSN22h
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?
With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...
Joplin Globe1d
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report ...
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...
MyChesCo on MSN1d
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024 ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...
marketinference4d
Shares of Moderna Are Down -6.9% -- Are They Valued Fairly?
Standing out among the Street's worst performers today is Moderna, a biotechnology company whose shares slumped -6.9% to a ...
Cautious Outlook for Moderna Amid Market Challenges and Shrinking Growth Prospects
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...